SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Morgan Stanleys designation of Amazon as a top pick, alongside optimism about AWS growth and AI initiatives such as Trainium, is driving attention. Many traders welcomed the sharp move, while others questioned the rally or discussed taking profits and looking for a pullback.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares are surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, strengthening the case for an FDA resubmission, though approval remains ahead and dizziness incidence has drawn some concern. Traders are broadly bullish on the trial result, with discussion also focused on short-covering and whether the rally can hold.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are drawing attention after a sharp selloff and break below technical support, with traders pointing to disclosed insider selling and a DBS downgrade as possible pressures. The community is divided between expecting further declines and viewing the pullback as a buying opportunity, while some also cite weakness in Indonesian markets and broader regional macro concerns.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs stronger-than-guided third-quarter results and upbeat 2027 EBITDA outlook have driven a sharp rally, with traders also pointing to short-covering and higher steel prices. The reaction is divided: bulls see room for continued gains, while skeptics warn the rally could fade and question whether the outlook can overcome the companys debt concerns.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is drawing attention for a sharp selloff despite the FDAs expanded ANKTIVA approval for papillary bladder cancer and encouraging long-term trial data. Traders debate whether the decline reflects sell-the-news profit-taking and broader biotech weakness, while others blame options-related pressure or short selling; concerns about revenue growth and future dilution also surface.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention after a steep post-IPO selloff, with traders citing share-unlock and insider-selling pressure, valuation and growth concerns, and broader weakness in AI and semiconductor stocks. Bulls are buying the dip and arguing the decline is overdone, while bears warn that selling could continue.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunruns continued share-price decline and heavy short interest dominate the discussion, with traders debating whether rate-sensitive solar-sector pressures and weak guidance outweigh the companys storage, virtual-power-plant, and AI data-center potential. Some see a possible short squeeze or recovery, while others expect further downside.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade of CoreWeave to Buy after a sharp selloff sparked a rebound attempt, but traders debated whether the call could overcome persistent selling. The main divide is between optimism about AI-compute demand and contracted backlog, and concern that heavy debt and financing costs could threaten the business.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almonty is drawing attention after a sharp selloff around its investor day, with traders divided over CEO Lewis Blacks presentation: some found the remarks positive, while others read his delivery as a sign of undisclosed problems. Bullish holders continue to cite the Sangdong production ramp and tungsten-supply outlook, while skeptics are focused on execution and the lack of clear reassurance.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicors raised Q3 growth outlook, driven by royalties from its Vertical Power Delivery licensing, is fueling positioning ahead of its earnings report. Traders are split between viewing the pullback despite stronger guidance and AI-power demand as an opportunity and worrying that volatility and high expectations could leave room for further weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPLPR NewswireNEW...

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit...

REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026

REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026 REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026PR NewswireNEW YORK, Sept. 24...

REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the FirmPR NewswireNEW YORK, Sept. 23, 2026...

REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses

REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff Deadline for Information About Recovering Their Losses REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2026 Lead Plaintiff...

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt

REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallStPR NewswireNEW YORK, Sept. 17, 2026 A chronology of...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPLPR NewswireNEW YORK, Sept. 16, 2026 Replimune...

REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky

Levi & Korsinsky, LLP alerts investors in Replimune Group, Inc. (NASDAQ: REPL) of a pending securities class action on behalf of purchasers between October 20, 2025 and April 10, 2026. Check if you might be eligible to recover your investment losses. You may also contact Joseph E. Levi, Esq. at...

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>J.M. Smucker climbed to nearly a three-year high of $134.85 after the company posted better-than-expected fiscal 2027 first-quarter results.&nbsp;</li><li>JPMorgan kept an ‘Overweight’ rating on Replimune and raised its price target to $21 from $20.&nbsp;</li><li>NeoGenomics secured expanded Medicare coverage for its RaDaR ST liquid biopsy test.&nbsp;</li></ul><p>J.M. Smucker Co. (SJM), Replimune Group (REPL) and NeoGenomics (NEO) hit fresh 52-week highs on Wednesday, fueled by company-specific catalysts. Improving volumes at Smucker, clinical momentum at Replimune and Medicare coverage for NeoGenomics’ cancer test gave investors fresh reasons to buy.&nbsp;</p><p>J.M. Smucker and NeoGenomics stocks gained over 4% and 3%, while Replimune stock climbed 0.5%.&nbsp;</p><h2 class="st-heading-2">J.M.&nbsp;Smucker Gains On Improving Volumes</h2><p><a href="https://stocktwits.com/symbol/SJM">J.M. Smucker stock</a> reached nearly a three-year high of $134.85 after the packaged-food company delivered stronger-than-expected first-quarter fiscal 2027 results. The performance prompted BTIG to increase its price target to $150 from $130 while keeping a ‘Buy’ rating.</p><p>The key signal for investors was a recovery in underlying product volumes. With Hostess excluded, each of Smucker’s operating businesses posted volume gains during the quarter. The company’s Q2 revenue of $2.2 billion and earnings of $3.24 both exceeded analysts' consensus expectations of $2.1 billion and $2.2 per share, respectively, according to Fiscal Ai data.&nbsp;</p><p>On Stocktwits, retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">Replimune Builds On Clinical Momentum</h2><p><a href="https://stocktwits.com/symbol/REPL">Replimune stock</a> climbed to an annual high of $15.99 as investors continued to respond to developments surrounding its cancer-treatment pipeline. JPMorgan raised its price target to $21 from $20 and maintained an ‘Overweight’ rating.</p><p>The firm pointed to support from key opinion leaders for the company’s approach to treating melanoma patients whose disease has stopped responding to PD-1 therapies. Replimune’s Tudriqev program has emerged as an important part of that opportunity as the company advances through major regulatory approvals.</p><p>Retail sentiment around the stock remained in ‘bullish’ territory.&nbsp;</p><h2 class="st-heading-2">NeoGenomics Gets A Reimbursement Boost</h2><p><a href="https://stocktwits.com/symbol/NEO">NeoGenomics stock</a> also reached a new 52-week high of $17.45. The company received a Medicare coverage determination for its RaDaR ST liquid biopsy test, which is designed to help detect minimal residual disease and assess treatment response.</p><p>Medicare reimbursement could make it easier for physicians to include the test in cancer care. The decision could expand NeoGenomics' commercial opportunity by reducing a major hurdle to wider adoption by oncology practices. However, retail sentiment around the stock remained in ‘bearish’ territory.</p><p>So far this year, SJM, REPL and NEO stocks have gained between 33% and 63%.&nbsp;</p><p>Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/anf-stock-is-on-fire-after-strong-q2-why-jefferies-still-sees-18-more-upside/cZY8mnGRJpO">ANF Stock Is On Fire After ‘Strong Q2’ — Why Jefferies Still Sees 18% More Upside</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, a hand holds a smartphone displaying the logo of The J.M. Smucker Company.

Earnings, drug development, and healthcare reimbursement fueled the stock rallies.

Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today?

Earnings, drug development, and healthcare reimbursement fueled the stock rallies. 

Neogenomics Inc.

J.M. Smucker Co.

$CRWV

$LKNCY

$REPL

$ZETA

$CRWV, $LKNCY, $REPL, and $ZETA are four of the most searched and talked-about stocks among retail investors this morning. Which are you most bullish on? Drop your reasoning in the comments.

Which of these trending stocks are you most bullish on for the next 12 months - $CRWV, $LKNCY, $REPL, or $ZETA?

Current Price	$10.76
Prev Close	$10.86
Open	$11.04
Dividend Yield	0.00%
50-Day Moving Average	$13.77
Beta	0.55
Avg. Volume	2.12M
PE Ratio	-3.31

52-Week High	$16.33
52-Week Low	$1.50
Market Capitalization	$1.02B
EPS (Annual)	-$3.38
Price to Book	8.63
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

REPL Fundamentals